Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Man Kit Siu, Wassim Abou-Kheir, Juan Juan Yin, Yung Sheng Chang, Ben Barrett, Florent Suau, Orla Casey, Wei Yu Chen, Lei Fang, Paul Hynes, Yao Yu Hsieh, Yen Nien Liu, Jiaoti Huang, Kathleen Kelly

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down regulation, activation of the EGFR pathway via altered expression of EGFR ligands (EREG and TGFA) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.

Original languageEnglish
Pages (from-to)3770-3784
Number of pages15
JournalOncotarget
Volume5
Issue number11
Publication statusPublished - 2014

Fingerprint

Bone Neoplasms
Protein-Tyrosine Kinases
Prostatic Neoplasms
Neoplasm Metastasis
Apoptosis Regulatory Proteins
Ligands
erbB-1 Genes
Bone and Bones
Drug Resistance
Heterografts
Therapeutics
Down-Regulation

Keywords

  • Bone metastasis
  • Epidermal growth factor receptor (EGFR)
  • KRAS
  • miR-203
  • Prostate cancer
  • Tyrosine kinase inhibitors (TKIs) resistance

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Siu, M. K., Abou-Kheir, W., Yin, J. J., Chang, Y. S., Barrett, B., Suau, F., ... Kelly, K. (2014). Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget, 5(11), 3770-3784.

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. / Siu, Man Kit; Abou-Kheir, Wassim; Yin, Juan Juan; Chang, Yung Sheng; Barrett, Ben; Suau, Florent; Casey, Orla; Chen, Wei Yu; Fang, Lei; Hynes, Paul; Hsieh, Yao Yu; Liu, Yen Nien; Huang, Jiaoti; Kelly, Kathleen.

In: Oncotarget, Vol. 5, No. 11, 2014, p. 3770-3784.

Research output: Contribution to journalArticle

Siu, MK, Abou-Kheir, W, Yin, JJ, Chang, YS, Barrett, B, Suau, F, Casey, O, Chen, WY, Fang, L, Hynes, P, Hsieh, YY, Liu, YN, Huang, J & Kelly, K 2014, 'Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance', Oncotarget, vol. 5, no. 11, pp. 3770-3784.
Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F et al. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 2014;5(11):3770-3784.
Siu, Man Kit ; Abou-Kheir, Wassim ; Yin, Juan Juan ; Chang, Yung Sheng ; Barrett, Ben ; Suau, Florent ; Casey, Orla ; Chen, Wei Yu ; Fang, Lei ; Hynes, Paul ; Hsieh, Yao Yu ; Liu, Yen Nien ; Huang, Jiaoti ; Kelly, Kathleen. / Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. In: Oncotarget. 2014 ; Vol. 5, No. 11. pp. 3770-3784.
@article{e2a1becea2d044a8bc0bad575b9fdbb3,
title = "Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance",
abstract = "Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down regulation, activation of the EGFR pathway via altered expression of EGFR ligands (EREG and TGFA) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.",
keywords = "Bone metastasis, Epidermal growth factor receptor (EGFR), KRAS, miR-203, Prostate cancer, Tyrosine kinase inhibitors (TKIs) resistance",
author = "Siu, {Man Kit} and Wassim Abou-Kheir and Yin, {Juan Juan} and Chang, {Yung Sheng} and Ben Barrett and Florent Suau and Orla Casey and Chen, {Wei Yu} and Lei Fang and Paul Hynes and Hsieh, {Yao Yu} and Liu, {Yen Nien} and Jiaoti Huang and Kathleen Kelly",
year = "2014",
language = "English",
volume = "5",
pages = "3770--3784",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "11",

}

TY - JOUR

T1 - Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

AU - Siu, Man Kit

AU - Abou-Kheir, Wassim

AU - Yin, Juan Juan

AU - Chang, Yung Sheng

AU - Barrett, Ben

AU - Suau, Florent

AU - Casey, Orla

AU - Chen, Wei Yu

AU - Fang, Lei

AU - Hynes, Paul

AU - Hsieh, Yao Yu

AU - Liu, Yen Nien

AU - Huang, Jiaoti

AU - Kelly, Kathleen

PY - 2014

Y1 - 2014

N2 - Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down regulation, activation of the EGFR pathway via altered expression of EGFR ligands (EREG and TGFA) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.

AB - Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down regulation, activation of the EGFR pathway via altered expression of EGFR ligands (EREG and TGFA) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.

KW - Bone metastasis

KW - Epidermal growth factor receptor (EGFR)

KW - KRAS

KW - miR-203

KW - Prostate cancer

KW - Tyrosine kinase inhibitors (TKIs) resistance

UR - http://www.scopus.com/inward/record.url?scp=84903539754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903539754&partnerID=8YFLogxK

M3 - Article

C2 - 25004126

AN - SCOPUS:84903539754

VL - 5

SP - 3770

EP - 3784

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -